Sunitinib in Pancreatic Neuroendocrine Tumors Abstract #708

Introduction: Sunitinib has shown significant improvement of progression-free survival in patients with advanced pancreatic neuroendocrine tumors (pNET).
Aim(s): Assessment of efficacy, safety and tolerability in clinical practice.
Materials and methods: Patients with advanced, differentiated (G1, G2) pNET treated with sunitinib between 2011 and 2012 in Essen and Marburg, Germany, were evaluated in terms of response to therapy, side effects and dose adjustments. All patients had progressive disease when starting sunitinib. Twenty-one patients (six males), median age 64 years (range 28-78) were included in the study.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Harald Lahner
Keywords: sunitinib, pNET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST
#1014 Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Krystallenia Alexandraki
#1385 The Efficiency of Sunitinib in Chinese Patients with Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Introduction: Systemic therapies for advanced Pancreatic neuroendocrine tumors (pNETs) are various. Sunitinib has shown its efficiency in pNET in clinical trials. While the efficiency of sunitinib in Chinese pNETs has not reported yet.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Heli Gao
Authors: Gao H, Cheng Y, Bai C M, ...